What is HC Wainwright’s Forecast for MCRB Q2 Earnings?

Seres Therapeutics, Inc. (NASDAQ:MCRB) – Investment analysts at HC Wainwright issued their Q2 2026 earnings estimates for shares of Seres Therapeutics in a research note issued to investors on Tuesday, June 23rd. HC Wainwright analyst M. Keller anticipates that the biotechnology company will earn ($2.07) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $12.00 price target on the stock. HC Wainwright also issued estimates for Seres Therapeutics’ Q3 2026 earnings at ($0.90) EPS, Q4 2026 earnings at ($0.93) EPS, FY2026 earnings at ($5.84) EPS, FY2027 earnings at ($2.87) EPS and FY2028 earnings at ($3.03) EPS.

Seres Therapeutics (NASDAQ:MCRB) last posted its earnings results on Tuesday, May 5th. The biotechnology company reported ($2.08) earnings per share for the quarter, missing the consensus estimate of ($1.88) by ($0.20). The business had revenue of $0.36 million during the quarter, compared to analysts’ expectations of $0.36 million.

MCRB has been the topic of several other research reports. Wall Street Zen upgraded Seres Therapeutics from a “strong sell” rating to a “sell” rating in a report on Saturday, June 6th. Canaccord Genuity Group reissued a “buy” rating and set a $22.00 target price on shares of Seres Therapeutics in a research note on Friday, March 13th. Finally, Weiss Ratings downgraded shares of Seres Therapeutics from a “sell (d)” rating to a “sell (d-)” rating in a report on Monday, May 18th. Two analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $17.00.

Seres Therapeutics Price Performance

Shares of Seres Therapeutics stock opened at $7.05 on Wednesday. Seres Therapeutics has a 1 year low of $5.31 and a 1 year high of $29.98. The business has a 50-day moving average of $7.46 and a two-hundred day moving average of $10.67. The company has a market capitalization of $68.24 million, a P/E ratio of -1.36 and a beta of 0.13.

Institutional Trading of Seres Therapeutics

Institutional investors have recently modified their holdings of the company. Invesco Ltd. grew its holdings in shares of Seres Therapeutics by 193.2% during the first quarter. Invesco Ltd. now owns 136,572 shares of the biotechnology company’s stock worth $96,000 after buying an additional 89,995 shares in the last quarter. Goldman Sachs Group Inc. lifted its stake in Seres Therapeutics by 40.9% in the 1st quarter. Goldman Sachs Group Inc. now owns 74,629 shares of the biotechnology company’s stock valued at $52,000 after acquiring an additional 21,679 shares in the last quarter. Marshall Wace LLP bought a new stake in Seres Therapeutics in the 2nd quarter valued at approximately $1,016,000. Vanguard Group Inc. boosted its position in Seres Therapeutics by 6.8% during the 3rd quarter. Vanguard Group Inc. now owns 311,889 shares of the biotechnology company’s stock worth $6,001,000 after acquiring an additional 19,793 shares during the last quarter. Finally, Schonfeld Strategic Advisors LLC acquired a new position in Seres Therapeutics during the 3rd quarter worth approximately $557,000. 59.34% of the stock is currently owned by institutional investors.

Seres Therapeutics Company Profile

Seres Therapeutics is a clinical?stage microbiome therapeutics company focused on harnessing the power of the human microbiome to treat serious diseases. Headquartered in Cambridge, Massachusetts, Seres applies proprietary microbiome science and manufacturing capabilities to develop a pipeline of living microbial therapies designed to restore healthy gut function. The company’s approach leverages understanding of microbial ecology and human biology to address conditions where the native microbiome is disrupted.

Among its lead candidates is SER-109, an investigational oral microbiome therapeutic for reducing recurrence of Clostridioides difficile infection.